clinical trial · NCT05818085
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
Atom Therapeutics Co., Ltd·phase3·completed·n = 300
GoutABP-671AllopurinolPlacebo
brief summary
This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.
started
Aug 11, 2023
primary completion
Jan 30, 2025
completion
Mar 30, 2025
last updated
Dec 22, 2025
official title
A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol